BEAM
Price
$17.27
Change
+$0.11 (+0.64%)
Updated
Jun 5, 01:58 PM (EDT)
Capitalization
1.72B
68 days until earnings call
ZYME
Price
$11.95
Change
-$0.25 (-2.05%)
Updated
Jun 5, 10:48 AM (EDT)
Capitalization
850.14M
Interact to see
Advertisement

BEAM vs ZYME

Header iconBEAM vs ZYME Comparison
Open Charts BEAM vs ZYMEBanner chart's image
Beam Therapeutics
Price$17.27
Change+$0.11 (+0.64%)
Volume$550
Capitalization1.72B
Zymeworks
Price$11.95
Change-$0.25 (-2.05%)
Volume$1.35K
Capitalization850.14M
BEAM vs ZYME Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. ZYME commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and ZYME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (BEAM: $17.15 vs. ZYME: $12.20)
Brand notoriety: BEAM and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 56% vs. ZYME: 50%
Market capitalization -- BEAM: $1.72B vs. ZYME: $850.14M
BEAM [@Biotechnology] is valued at $1.72B. ZYME’s [@Biotechnology] market capitalization is $850.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 3 bearish.
  • ZYME’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +0.70% price change this week, while ZYME (@Biotechnology) price change was +8.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.55%. For the same industry, the average monthly price growth was +10.38%, and the average quarterly price growth was -1.93%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

ZYME is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+4.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.73B) has a higher market cap than ZYME($850M). ZYME YTD gains are higher at: -16.667 vs. BEAM (-30.847). ZYME has higher annual earnings (EBITDA): -110.05M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. ZYME (265M). ZYME has less debt than BEAM: ZYME (18.5M) vs BEAM (158M). ZYME has higher revenues than BEAM: ZYME (93.4M) vs BEAM (63.6M).
BEAMZYMEBEAM / ZYME
Capitalization1.73B850M203%
EBITDA-399.03M-110.05M363%
Gain YTD-30.847-16.667185%
P/E RatioN/AN/A-
Revenue63.6M93.4M68%
Total Cash1.22B265M460%
Total Debt158M18.5M854%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
91
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
67
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMZYME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 15 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDTRX191.55N/A
N/A
Franklin DynaTech R6
FGILX22.61N/A
N/A
Fidelity Global Equity Income
IVOCX18.43N/A
N/A
Macquarie Mid Cap Income Opps C
PIIMX28.65N/A
N/A
Principal Glb Emerging Markets R6
VEOIX20.83N/A
N/A
Vanguard Global Environmental Opp StkInv

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with ABCL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+0.99%
ABCL - ZYME
48%
Loosely correlated
+4.76%
LENZ - ZYME
48%
Loosely correlated
-1.95%
NRIX - ZYME
46%
Loosely correlated
+0.66%
BEAM - ZYME
45%
Loosely correlated
+1.60%
KYMR - ZYME
45%
Loosely correlated
+1.56%
More